All In Biotech

Drug Trial Radar · NCT05583617

A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma

A Platform Study Evaluating the Safety and Efficacy of Multiple Treatments in Patients With Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Nov 14, 2023

Primary completion

Jul 31, 2028

Study completion Jul 31, 2028

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Oct 18, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

CO43923 is a platform study that will evaluate the safety, efficacy, and pharmacokinetics (PK) of multiple treatment combinations, as monotherapy or in combination, in participants with multiple myeloma (MM). The study is designed with the flexibility to open new treatment substudies as new treatments become available. Information regarding the opened substudies are found below.

Conditions

  • Multiple Myeloma

Interventions

  • CevostamabDrug

    Substudy 2: Cevostamab will be administered intravenously (IV) on a 28-day cycle, up to a total of 13 cycles. Substudy 4: Cevostamab will be administered by IV on a 21-day cycle, up to a total of 17 cycles.

  • LenalidomideDrug

    Lenalidomide will be administered PO on days 1-21 of a 28-day cycle.

  • TocilizumabDrug

    Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.

  • IberdomideDrug

    Iberdomide will be administered PO on days 1-14 of a 21-day cycle.

  • DexamethasoneDrug

    Dexamethasone will be administered on Days 2 and 8 of Cycles 1-3.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Stage 1: Percentage of Participants with Adverse Events (AEs)Time frame: Baseline up to approximately 5 years
  2. Stage 2: Objective Response Rate (ORR)Time frame: Baseline up to approximately 5 years
  3. Stage 2: Complete Response (CR) or Stringent Complete Response (sCR) RateTime frame: Baseline up to approximately 5 years
  4. Stage 2: Rate of Very Good Partial Response (VGPR) or BetterTime frame: Baseline up to approximately 5 years
  5. Stage 2: Progression-free Survival (PFS)Time frame: Baseline up to approximately 5 years
  6. Stage 2: Overall Survival (OS)Time frame: Baseline up to approximately 5 years

Locations

16 sites in 6 countries. Site status is shown where the registry gives one.

  • Prince of Wales Hospital

    Randwick, New South Wales, Australia · Recruiting

  • St Vincent's Hospital Melbourne

    Fitzroy, Victoria, Australia · Recruiting

  • CHU Lyon Sud - Service Hématologie

    Pierre-Bénite, France · Recruiting

  • IUCT Oncopole

    Toulouse, France · Recruiting

  • Hopital Bretonneau

    Tours, France · Recruiting

  • IGR

    Villejuif, France · Withdrawn

  • Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II

    Hamburg, Germany · Recruiting

  • Universitätsklinikum Leipzig - Klinik und Poliklinik für Hämatologie

    Leipzig, Germany · Recruiting

  • Uniwersyteckie Centrum Kliniczne

    Gda?sk, Poland · Recruiting

  • Szpital Kliniczny Ministerstwa Spraw Wewnetrznych i Administracji z Warminsko-Mazurskim Centrum Onkologii w Olsztynie

    Olsztyn, Poland · Recruiting

  • Uniwersytecki Szpital Kliniczny w Poznaniu

    Późna, Poland · Withdrawn

  • Severance Hospital, Yonsei University Health System

    Seoul, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

  • Fundacion Jimenez Diaz

    Madrid, Spain · Recruiting

  • Hospital Clinico Universitario de Valencia

    Valencia, Spain · Recruiting

  • Hospital Universitari Germans Trias i Pujol

    Badalona, Barcelona, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.